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Abstract:
Introduction: We have previously demonstrated that pyrazolo[3,4-d]pyrimidines derivatives from the extensive library of compounds we have synthesized display inhibitory
action on the tyrosine kinases Src, Fyn and serine-threonine kinase SGK1 in the nanomolar range. Moreover, these compounds show antiproliferative effects on several cancer
cell lines in vitro [1]. Glioblastoma multiforme (GBM) is the most aggressive subset of brain cancer, showing high probability of recurrence and poor patient survival. Thus, our
project was to test three of our lead compounds on a series of patient derived GBM cell lines isolated from both the central tumor core and cells from the invasive margin of
the tumor; the latter of which are associated with disease reoccurrence due to the difficult nature in removing these cells during surgical procedures [2]. Therefore, performing
in vitro testing on these invasive cells (in addition to tumor core cells) represents an important step in the discovery and development of drugs for the treatment of GBM.
Unfortunately, one main lack of those pyrazolo[3,4-d]pyrimidines derivatives is their limited solubility in water, which affects bioavailability and in vivo efficacy. Accordingly, we
have generated solid dispersions whereby the inhibitors are molecularly dispersed in an inert hydrophilic polymeric carrier [3], in order to overcome these limitations and
generate formulations more viable for oral administration.
Methods: A miniaturized screening process, based on an inkjet printing technology, able to identify the best formulation to enhance the apparent water solubility was
performed on the three selected kinase inhibitors. On the basis of the ΔA% average results, we selected the best polymers able to solubilize the pyrazolo[3,4-d]pyrimidines in
water. The drugs formulated with the selected polymers were then tested against GBM cell lines and the potency compared to the drugs solubilized either in water or 0.5%
DMSO.
Results: It was found that Src and SGK1 inhibitors demonstrated the most potency against GBM cells. Furthermore, in vitro testing illustrates that printing 5 µg/mL of drug into
polymer dispersions at a level of 90% is a viable method for formulation, as potency was comparable to that of drug prepared in DMSO solutions.
Conclusion/Implications: Data demonstrate that our kinase inhibitors are attractive candidates for the treatment of GBM. Moreover, we report on a formulation strategy that
can be successfully applied to increase the water solubility of the inhibitors in a manner that does not compromise on potency, and thus provide a viable approach for
development of oral formulations.
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